For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Adipotide
Illustration for Adipotide

THE PEPSRADAR ENCYCLOPEDIA

Adipotide

Adipose vascular targeting in primates

Research topics · Sources checked 2026-10-04

Read the studies ↓

Adipotide · KEY FACTS

Content updated · how dates work

Saved peptides

What is Adipotide?

Adipotide is a peptidomimetic designed to target blood vessels in adipose tissue. Its featured study reported weight-related changes in obese monkeys and also identified kidney effects.

Biological role or research focus

Adipose vascular targeting in primates.

Primate results do not establish human efficacy. The reported reversibility of kidney changes does not make them unimportant or prove clinical safety.

Role reference: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. · 2011 ↗

Names you may encounter

FTPP · Fat-targeted proapoptotic peptide

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Experimental fat-vascular-targeting peptidomimetic
Research focus
Adipose vascular targeting in primates
Featured evidence
Animal study
Source check
October 4, 2026

Source: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. · 2011 ↗

Quick answers

Is Adipotide FDA approved?
No. No FDA-approved drug contains Adipotide. Source ↗
Is Adipotide safe?
Adipotide is an experimental fat-targeting peptidomimetic with no published human safety data. In obese monkeys it caused kidney tubule changes alongside weight loss. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
Is Adipotide banned in sport?
Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Animal / mixed laboratory research
StudyTypePopulation / model
Adipotide in obese nonhuman primates (2011)Animal studyObese Old World monkeys.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Animal study · 2011

Adipotide in obese nonhuman primates

What did this publication test, and what did it find?

Population / model
Obese Old World monkeys.
Study design
Animal intervention assessing weight, adipose tissue, insulin resistance, and safety measures.
Main finding
The investigators reported reductions in body weight and adipose tissue, with improved insulin-resistance measures. Renal proximal-tubule changes were also observed.
Limits & context
Primate results do not establish human efficacy. The reported reversibility of kidney changes does not make them unimportant or prove clinical safety.

Source: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. · 2011 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

No study naming Adipotide as an intervention was found on ClinicalTrials.gov when we last checked (November 14, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.

Further reading · 2 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. ↗
Journal of controlled release : official journal of the Controlled Release Society · 2013 Oct 28 · Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys". ↗
Science translational medicine · 2012 Apr 25 · Journal Article, Comment

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Adipotide is an experimental fat-targeting peptidomimetic with no published human safety data. In obese monkeys it caused kidney tubule changes alongside weight loss.

Human safety data: None

No published human safety results were found. Evidence comes from monkey studies, where kidney effects were a notable finding; the reported reversibility in monkeys does not show it is safe for people.

Unassessed: no human safety data

Warning signs in animal or lab studies: Kidney problems

It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Harms seen in animal or lab studies

  • Changes in kidney (proximal tubule) function in obese monkeys of three species, reported as reversible

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Adipotide in obese monkeys (Sci Transl Med, 2011) ↗

Safety & what remains unknown

Kidney tubular effects are a material finding in this study and should remain prominent in summaries.

Source: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. · 2011 ↗

Evidence boundaries

Primate results do not establish human efficacy. The reported reversibility of kidney changes does not make them unimportant or prove clinical safety.

Source: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. · 2011 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source
World Anti-Doping Agency (2026)
Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & identity

This is preclinical obesity research in nonhuman primates. The findings do not establish an effective or safe human weight-loss treatment.

Source: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. · 2011 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

Biology & proposed mechanism

The experimental strategy combines adipose-vascular targeting with a proapoptotic component. It differs from incretin-based appetite signaling.

Source: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. · 2011 ↗

Questions worth asking

  • Were kidney effects reported?
  • What material, population, and route were actually studied?
  • Primate results do not establish human efficacy. The reported reversibility of kidney changes does not make them unimportant or prove clinical safety.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Were kidney effects reported?

Yes. The publication described predictable, reversible proximal-tubule changes in its animal setting; this is not evidence that human kidney risk is absent.

Source: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. · 2011 ↗

Does the publication verify a supplier’s product?

No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.

Source: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. · 2011 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections